TTrialPathMatch Me to Trials
← Back to trials
RecruitingAutism Spectrum Disorder

Transcranial Magnetic Stimulation (TMS) to Treat Depression in Autism Spectrum Disorder

Eligible age

18–40 yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

Yes

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This study will assess clinical and behavioral measures along with electroencephalogram (EEG), event-related potentials (ERPS), and eye-tracking (ET) prior to and following a single intermittent Theta Burst Stimulation (iTBS) session to provide preliminary insight into the potential of TMS as an intervention for depression in individuals with Autism Spectrum Disorder (ASD).

Sponsor: Yale University

You may qualify if…

  • ✓ Individuals from Yale University and the surrounding community who are between the ages of 18 and 40 years old with or without a diagnosis of depression. Or individuals between the ages of 18 and 40 years old with a diagnosis of autism spectrum disorder, autistic disorder, PDD NOS, or Asperger syndrome with or without a diagnosis of depression.
  • ✓ A depression score on the HDRS-17 of at least 20 will be used as a cut-off for depression.
  • ✓ Participants are unmedicated or on stable medication treatment for at least two weeks.
  • ✓ Willingness and ability to participate in an EEG and eye-tracking procedure.
  • ✓ Provision of signed and dated informed consent.

You may not qualify if…

  • ✕ Participants reporting significant head trauma or serious brain illness.
  • ✕ Participants unable to provide signed informed consent.
  • ✕ Participants with major psychiatric illness that would preclude completion of study measures. Participants with diagnosis of a psychotic or bipolar illness with be excluded.
  • ✕ Participants with a history of serious medical illness, stroke, seizures, epileptiform EEG abnormalities, or family history of epilepsy.
  • ✕ Participants taking prescription medications that may affect cognitive processes under study.
  • ✕ Participants taking any medication that may increase their risk of seizures.
  • ✕ Participants who have taken alcohol or recreational drugs within the preceding 24 hours prior to the scheduled study visit as determined by the urine toxicology test.
  • ✕ Participants with a history of substance or alcohol abuse or dependence in the past 6 months.

Where it's recruiting

Connecticut

New Haven

Source: ClinicalTrials.gov · NCT06142955 · last updated 2026-07-16

Transcranial Magnetic Stimulation (TMS) to Treat Depression in Autism · TrialPath